Codexis, Inc. — Third Quarter 2026 Earnings Summary
Codexis, Inc. reported third-quarter 2026 total revenues of $19.3 million, a significant increase from $8.6 million in the same period of 2025, driven by higher product revenue from newly approved customer products. The company achieved a product gross margin of 74.5% for the quarter and reduced its net loss to $8.1 million, or $0.08 per share, compared to a $19.6 million loss in the prior year period. Financial stability was strengthened through a $25 million equity raise completed in July and a $60 million senior secured loan facility with Trinity Capital, which included a $42.5 million drawdown used to refinance existing debt. Codexis reiterated its full-year 2026 revenue guidance of $72 million to $76 million and expects its cash and investments to fund operations through the end of 2028.
- Company
- CODEXIS INC
- Sector
- Healthcare
- Industry
- Biotechnology